In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $48.51, marking a -0.84% move from the previous day. This change lagged the S&P 500's daily loss of 0.18%. Elsewhere, the Dow saw ...

We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds. In this article, we are going ...

Given this risk, we thought we'd take a look at whether CRISPR Therapeutics (NASDAQ:CRSP) shareholders should be worried ...

Longer Term Trading Plans for CRSP. Buy CRSP near 40.82 target 52.08 stop loss @ 40.7 Details; The technical summary data ...

In a report released today, Joon Lee from Truist Financial reiterated a Buy rating on Crispr Therapeutics AG (CRSP – Research Report).

Valuing small biotech firms with minimal revenue is challenging, yet CRISPR Therapeutics (NASDAQ:CRSP) appears undervalued at a $4.2 billion market cap. Following the approval of Casgevy ...

1 Day CRSP 1.98% DJIA 0.79% S&P 500 0.47% Health Care/Life Sciences -0.97% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...